# PK of Serelaxin in Severe Renal Impairment and ESRD

> **NCT01875523** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- Renal Failure, Chronic
- End-Stage Renal Disease

## Interventions

- **DRUG:** Serelaxin

## Key facts

- **NCT ID:** NCT01875523
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01875523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01875523, "PK of Serelaxin in Severe Renal Impairment and ESRD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01875523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*